Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. develops prescription transdermal pharmaceutical products, with recurring updates centered on its AVERSA abuse-deterrent transdermal technology and a lead abuse-deterrent fentanyl transdermal system. The technology incorporates aversive agents into patches to address abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulant drugs.
Company news also covers product distribution activity for kinesiology tapes and mosquito repellent patches, regulatory and intellectual-property steps tied to transdermal products, shareholder meeting matters, and corporate updates involving operating subsidiaries and Nasdaq-listed common stock and warrants.
Nutriband (NASDAQ: NTRB / NTRBW) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21 — Noble Capital Markets' 21st Emerging Growth Equity Conference in Boca Raton, FL on December 3, 2025 at 9:30 AM ET.
Interested investors may register at a discounted rate using code NTRBNOBLECON. A high-definition webcast will be posted the following day on nobleconference.com and channelchek.com and archived for 90 days.
Nutriband develops transdermal pharmaceuticals; its lead program is an abuse-deterrent fentanyl patch using AVERSA™ technology.
Nutriband (NASDAQ:NTRB) received final meeting minutes from a Sept 18, 2025 virtual face-to-face meeting with the US FDA regarding its lead product AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system. FDA confirmed the regulatory pathway as a 505(b)(2) NDA and provided CMC feedback on registration batch plans, manufacturing process validation, product specifications, stability testing, and planned Category 1 in vitro manipulation/extraction studies. Nutriband is incorporating FDA guidance as it advances toward an IND filing to support a Human Abuse Potential (HAP) clinical study. The company partners with Kindeva and cites a peak US sales potential of $80M–$200M. Nutriband holds patents in 46 countries.
Nutriband (NASDAQ: NTRB / NTRBW) announced that co-founder Gareth Sheridan has returned as CEO effective October 27, 2025. From August 10 to October 27, co-founder and chairman Serguei Melnik covered CEO duties.
Mr. Sheridan will lead the company through the remainder of 2025 toward a targeted NDA filing in 2026 for AVERSA FENTANYL, an abuse‑deterrent transdermal fentanyl patch. Management cites a Health Advances market analysis estimating peak U.S. sales of $80M–$200M. The AVERSA technology is protected by patents in 46 countries.
Nutriband (NASDAQ:NTRB / NTRBW) announced on October 10, 2025 that its 4P Therapeutics subsidiary signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, the development-named AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system using AVERSA™ technology.
Brand Institute will provide naming and identity services and regulatory support via its Drug Safety Institute, leveraging prior experience with drug-name approvals and regulatory naming guidance.
Nutriband (NASDAQ:NTRB) filed a provisional patent application with the USPTO on October 8, 2025 to strengthen intellectual property covering its AVERSA™ transdermal abuse deterrent technology. The filing targets improved aversive formulations and coating application methods designed to enhance deterrence for patches containing opioids and stimulants.
The company notes AVERSA is already covered by issued patents in 46 countries and says conversion to a non‑provisional application and a subsequent patent grant could extend U.S. patent protection (statutory term starts from the non‑provisional filing date).
Nutriband (NASDAQ: NTRB / NTRBW) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. Chairman Serguei Melnik will deliver a formal presentation including a fireside Q&A at 3:00 PM Eastern, with live questions from the virtual audience.
Registered, qualified investors may request scheduled 1x1 meetings with management by contacting Giorgia Pigato at Noble Capital Markets. The live webcast will be available via Channelchek and will be archived on the company website and Channelchek for 90 days. Registration for the live presentation is free for attendees.
Nutriband Inc. (NASDAQ:NTRB) has announced its participation in the upcoming MicroCap Rodeo Conference in New York City on September 25, 2025. Company Chairman Serguei Melnik will deliver a presentation at 10:00 AM, focusing on operational highlights, growth initiatives, and the company's AVERSA platform technology.
The presentation will be available via live webcast, and management will conduct one-on-one meetings with approved investors. Interested parties can register for the virtual presentation through the conference website at www.microcaprodeo.com.
Nutriband (NASDAQ:NTRB) reported strong Q2 2025 financial results, with revenue reaching $1,289,884, marking a 50.87% increase year-over-year. The company maintains a robust cash position of $6.9 million, with total assets of $10.17 million and stockholders' equity of $8.5 million.
The company is advancing its lead product, AVERSA Fentanyl, with a scheduled Type C meeting on September 18th. Notably, the NDA filing will require only a single phase 1 Human Abuse Potential study, without the need for Phase 2 or 3 trials. Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband (NASDAQ:NTRB) has announced the exercise of warrants at a strike price of $6.43, generating gross proceeds of $5,306,000. The company will utilize these funds primarily for completing the clinical development of AVERSA Fentanyl and submitting its New Drug Application (NDA) to the FDA for marketing approval.
AVERSA Fentanyl is positioned to potentially become the first opioid patch with abuse deterrent properties. According to the Health Advances Aversa Fentanyl market analysis report 2022, the product could achieve peak annual US sales between $80 million to $200 million.
Nutriband Inc. (NASDAQ: NTRB) has announced its participation in the upcoming Emerging Growth Conference on August 20, 2025. The company's Chairman, Serguei Melnik, will deliver a presentation at 09:40 AM Eastern time for 30 minutes.
The interactive online event will allow shareholders and investors to engage directly with management through a Q&A session. Questions can be submitted in advance to Questions@EmergingGrowth.com or during the live event. For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.